Economic evaluation of Danhong injection for the treatment of chronic stable angina in China: A cost-effectiveness analysis
Open Access
- 18 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Science of Traditional Chinese Medicine
- Vol. 2 (4) , 284-290
Abstract
Objective: Danhong injection (DHI) is commonly used in China to treat chronic stable angina (CSA), demonstrating significant clinical efficacy and safety. The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment (ST) compared with ST alone in patients with CSA. Methods: A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI + ST for CSA. Health outcomes were measured as quality-adjusted life years (QALYs), and societal perspective costs were collected in China. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to test the robustness of results to parameter uncertainty. Results: Analysis demonstrated DHI + ST provided 0.8190 QALYs at an average cost of $3644.24, while ST yielded 0.7884 QALYs costing $2739.54 over 1 year. The incremental analysis indicated DHI + ST dominance, with an ICER of $29,588.91 per QALY gained compared with ST. One-way sensitivity analysis confirmed the robustness of base case findings, and probabilistic sensitivity analysis suggested a 61.66% probability of DHI + ST being cost-effective over ST at a $37,663.26 per QALY threshold. Conclusion: From a societal perspective in China, DHI + ST appears cost-effective for the treatment of CSA compared with ST alone. These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.Keywords
This publication has 24 references indexed in Scilit:
- Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness AnalysisPharmacoEconomics, 2023
- Diagnosis and Management of Stable AnginaJAMA, 2021
- Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018PharmacoEconomics, 2020
- The new definition of health technology assessment: A milestone in international collaborationInternational Journal of Technology Assessment in Health Care, 2020
- Scientific Development of HTA—A Proposal by the Health Technology Assessment International Scientific Development and Capacity Building CommitteeInternational Journal of Technology Assessment in Health Care, 2019
- Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY StudiesValue in Health, 2018
- Cost-Effectiveness Thresholds: the Past, the Present and the FuturePharmacoEconomics, 2018
- Mapping to Obtain EQ-5D Utility Values for Use in NICE Health Technology AssessmentsValue in Health, 2013
- The Prevalence of Weekly Angina Among Patients With Chronic Stable Angina in Primary Care PracticesArchives of internal medicine (1960), 2009
- Development and evaluation of the Seattle Angina questionnaire: A new functional status measure for coronary artery diseaseJACC, 1995